Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21687944 | 0.92 | PTGER4 (0.30) | — | |
| SCHEMBL21687901 | 0.91 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2MEN1TSHRKMT2A | |
| SCHEMBL21687618 | 0.86 | SMN1; SMN2 (0.35) | ALDH1A1SMN1; SMN2MEN1TSHRKMT2A | |
| SCHEMBL21687915 | 0.86 | SMN1; SMN2 (0.34) | ALDH1A1SMN1; SMN2MEN1TSHRKMT2A | |
| SCHEMBL21687889 | 0.85 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2MEN1TSHRKMT2A | |
| SCHEMBL21688063 | 0.84 | PDE9A (0.34) | ALDH1A1SMN1; SMN2MEN1TSHRKMT2A | |
| SCHEMBL21687778 | 0.83 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2KDM4EATML3MBTL1 | |
| SCHEMBL21687930 | 0.83 | PTGER4 (0.30) | ALDH1A1KDM4E | |
| SCHEMBL21687635 | 0.83 | SMN1; SMN2 (0.37) | ALDH1A1SMN1; SMN2MEN1TSHRKMT2A | |
| SCHEMBL21688131 | 0.81 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2MEN1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11201300-B2 | Condensed cyclic compound and organic light-emitting device including condensed cyclic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2021-12-14 | — | — | US | disclosed |
| US-20200044168-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200044168-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING CONDENSED CYCLIC COMPOUND | CRY1, CCNL2, CCNE2 | ALDH1A1 616/4885SMN1; SMN2 4039/4885MEN1 669/4885 |
| US-11201300-B2 | Condensed cyclic compound and organic light-emitting device including condensed cyclic compound | CRY1, CCNL2, CCNE2 | ALDH1A1 616/4885SMN1; SMN2 4039/4885MEN1 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.